|
 Nicostop |
 |
Nicostop is the first domestically developed transdermal nicotine patch
that helps stop
smoking. Smokers apply Nicostop patches to their shoulder,
arm, and thigh to
continuously supply a steady amount of nicotine through
their skin, minimizing the
withdrawal symptoms caused by smoking
cessation, thus helping to successfully quit
smoking. |
|
|
| Rheumastop |
Rheumastop plaster is a diclofenac (an analgesic and anti-inflammatory drug)
containing transdermal drug delivery system for symptomatic relief of pain caused
by rheumatic arthritis.
Rheumastop also has superior adhesiveness, outstanding
joint-penetrating power, and a longer
medicinal effect, and is easy and convenient
for arthritis patients to use. |
 |
|
| Estran Combitran |
Estran patch is a drug for treating post-menopausal syndrome (PMS).
When applied to the skin, it continuously supplies appropriate amounts of
estrogen to the body,
thus treating PMS symptoms.
Estran is indicated for the treatment of PMS syndrome in hysterectomized
female patients. Combitran,first developed in Korea by Samyang contains estradiol and
progesterone, is indicated for the treatment of PMS of common female patients. |
 |
|
 |
|
| Angiderm |
Angiderm patch is indicated for prevention of angina pectoris.
It is manufactured in the form of a matrix-type patch that is smaller, thinner,
and more transparent than existing patches, thus giving its user more comfort.
It has excellent adhesiveness and does not easily peel off in the shower or
while swimming. It causes nearly no side effects to the skin. |
 |
|
|
| Biomesh |
 |
Guided Tissue Regeneration (GTR) BioMesh is a bio-decomposable product that does
not require the second removal surgery after it is implanted in the periodontal tissue.
Since it does not use a plasticizer, it reduces concerns over infection and works well
in regenerating the periodontal tissue. It has been given ISO 9001 and EN 46001
certifications, as well as the U.S. FDA? 510(K) certification, in 1999, and Europe?
CE Mark in 2002. |
|
|
| Trisorb Monosorb |
 |
Trisorb is a bio-absorbable suture in the form of multiple filaments that is
decomposed and absorbed in the body. It is currently exported to Europe,
the United States, North America, and China, where it is winning favorable
acclaim. Monosorb, developed in the form of a monofilament, is exported
to the United States, Europe, and Asia. Both have been conferred ISO 9001
and EN 46001 certifications. |
|
|
| Surgisorb |
Surgisorb, which Samyang independently developed using its own technology,
is a synthetic, bio-absorbable surgical suture designed to minimize tissue reactions
such as infection while being absorbed. It is applied with a sterilized coating that
meets American and European accreditation standards. In 1999, it earned the U.S.
Food and Drug Administrations (FDA) 510(K) certification and Europe? CE Mark. |
 |
|
|
|
| Genexol Injection |
 |
Samyang developed its Genexol injection in June 2001, when paclitaxel
was successfully mass-produced in September 1995 using the world? first plant
cell cultivation technology. Genexol is a U.S. FDA-approved anti-cancer compound
that is tremendously effective in combating breast, ovarian, and lung cancers as
well as AIDS-related Kaposi? sarcoma. It is produced through plant tissue
cultivation,
thus allowing stable, uniform-quality, and environment-friendly
mass-production.
It is now being used worldwide. |
|
|
| Genexol-PM |
Genexol-PM injection is Samyang? clinically most advanced formulation of potent anticancer drug;
paclitaxel.The polymeric micelles (PM) for paclitaxel has several advantages over conventional cremophore
based formulations such ability to provide higher dose of paclitaxel and thereby resulting in high tumor
concentration. Genexol-PM is undergoing phase human clinical investigation in USA in a selected cancer.
The Korean development of Genexol-PM is progressing rapidly and three Phase clinical studies in breast
and lung cancers are expected to conclude within year 2005 with the hope product launch in year 2006. |
|
|
|
|
